亚洲 · 综合新闻 · The Japan Times
Health ministry questions reliability of vasculitis drug approval data
Tavneos was launched in Japan in 2022 after being approved by the ministry. Its package insert listed liver dysfunction as a serious side effect.
在 The Japan Times 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.japantimes.co.jp)





